All patients about to receive cancer treatment for haematological or solid tumours should be tested for hepatitis B virus (HBV) due to the risk of immunosuppressive treatment reactivating infection, specialists say.

New recommendations, published in the Medical Journal of Australia on Monday, are aimed at streamlining the screening and treatment protocol and overcoming current inconsistencies in clinical practice.